Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Fig. 5

Repression of EGFR is an obligatory intermediate step for KLF4 to inhibit aggressive breast cancer phenotypes. MCF10A cells were transfected with siNS, siKLF4, siEGFR, or siKLF4+siEGFR, and western blots were performed to confirm a KLF4 and b EGFR silencing. Cells were then allowed to c migrate for 6 h or d invade for 16 h before they were stained and counted. e MCF10A cells were transfected with siNS, siKLF4, siEGFR, or siKLF4+siEGFR, and cell number was counted at days 3–5 using trypan blue exclusion assay, *p < 0.05. f Apoptotic MCF10A cells were assessed using Hoechst stain 3 days after transfection. g EdU staining was used to quantify the number of proliferating MCF10A cells 3 days post-transfection. For all data, relative values were normalized versus the control, and error bars represent the standard deviation. Bars with distinct letters above them are significantly different from one another (p < 0.05). Experiments were performed three independent times in triplicate

Back to article page